Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 18, 2021

Study Completion Date

December 18, 2021

Conditions

Congenital Hyperinsulinaemic HypoglycaemiaOctreotide Adverse Reaction

Interventions

DRUG

Octreotide Injection

Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine

Trial Locations (1)

Department of Endocrinology, Genetics, Metabolism, Beijing

All Listed Sponsors

lead

Beijing Children's Hospital

OTHER

NCT05171751 - Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia | Biotech Hunter | Biotech Hunter